What does CUSIP 03771D102 represent in this 13F holders report?

CUSIP 03771D102 is the security identifier for APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock in Q3 2025?

8 institutional investors reported APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock for Q3 2025. Use the holders table for investor-level position and value details.

Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS)

CUSIP: 03771D102

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Stock
Shares outstanding: 12,584,892
Total 13F shares: 399,983
Share change: +121,452
Total reported value: $711,810
Price per share: $1.78
Number of holders: 8
Value change: +$221,594
Number of buys: 7
Number of sells: 4

Quarterly Holders Quick Answers

What is CUSIP 03771D102?
CUSIP 03771D102 identifies APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2025

Recent filing periods for CUSIP 03771D102:

Q4 2025 Q3 2025 Q2 2025

Top shareholders of APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Inscobee Inc.	3/4/5	10%+ Owner	34%	4,316,618	$8,805,900	—	12 May 2025	3/4/5
Yorkville Advisors Global, LP	13F	Company	2%	250,000	$440,000	—	30 Jun 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.11%	13,359	$23,512	—	30 Jun 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.1%	11,987	$21,097	—	30 Jun 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.03%	3,151	$5,546	—	30 Jun 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	29	$52	—	30 Jun 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	5	$9	—	30 Jun 2025	13F

Institutional Holders of Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) as of Q3 2025

As of 30 Sep 2025, Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) was held by 8 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 399,983 shares. The largest 8 holders included Hemenway Trust Co LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, XTX Topco Ltd, HRT FINANCIAL LP, BANK OF AMERICA CORP /DE/, and JPMORGAN CHASE & CO. This page lists 8 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

Q3 2025 holders

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.